Pharmacogenetic study in metastatic colorectal cancer (CRC) patients receiving third-line panitumumab-irinotecan: A GERCOR ancillary study.

摘要: 2537^ Background: Test the predictive value of gene polymorphisms potentially linked to panitumumab and irinotecan pharmacodynamics. Methods: 45 patients with metastatic CRC refractory standard therapy were enrolled in this ancillary pharmacogenetic study as part a phase II trial that included 63 patients. Inclusion required wild-type KRAS tumor status (codons 12-13, analyses performed each center). After inclusion, central re-assessment was 12-13-59-61) 9 over found carry mutation. Patients received (6 mg/kg, day 1) associated (180 mg/m2, 1), Q2W until disease progression or unacceptable toxicity. Analyzed on blood DNA : EGFR (CA repeats intron 1, -216G>T, -191C>A), EGF (61A>G), CCND1 (870A>G), UGT1A1 (*28). Results: Cutaneous toxicity imputable i.e. folliculitis paronychia not EGFR, polymorphisms. Diarrhea (12 grade 13 2, 8 3) w...